Trial reportJournal of clinical hypertension (Greenwich, Conn.)2021
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes.Annals of medicine · 2025Pooled it
- Effect of the Xanthine Oxidase Inhibitor Febuxostat on the Cardio-Ankle Vascular Index in Asymptomatic Patients with Hyperuricemia and Liver Dysfunction: A Sub-Analysis of the PRIZE Study.Journal of atherosclerosis and thrombosis · 2025Trial
- Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Trial
- Targeted Treatment for Hyperuricemia: The Drug Pipeline.Drugs & aging · 2026Review
- Comparison of the incidence of proteinuria and changes in eGFR among febuxostat and topiroxostat users.Clinical and experimental nephrology · 2025Article
- Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan - A JMDC Claims Database Study.Circulation reports · 2025Article
- Association between serum uric acid levels and arterial stiffness in patients with psoriasis.Archives of dermatological research · 2025Article
- Article
- Review
- Relationship of Serum Uric Acid with Kidney Function Decline Mediated by Systemic Arterial Stiffness: A Retrospective Cohort Study in Japan.Diagnostics (Basel, Switzerland) · 2024Article
- Hyperuricemia research progress in model construction and traditional Chinese medicine interventions.Frontiers in pharmacology · 2024Review
- Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases.Biomolecules · 2023Review
- Impact of Hyper- and Hypo-Uricemia on Kidney Function.Biomedicines · 2023Review
- Article
- The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Uric acid, xanthine oxidase, and vascular damage: potential of xanthine oxidoreductase inhibitors to prevent cardiovascular diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Review of Urate-Lowering Therapeutics: From the Past to the Future.Frontiers in pharmacology · 2022Review
- Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation.JCI insight · 2021Article
- Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects. This multicenter, randomized, open-label study compared the effects of two XORi, topiroxostat and febuxostat, on arterial stiffness, uric acid levels, and BP in hypertensive patients with hyperuricemia. Patients received topiroxostat 40-160 mg/day or febuxostat 10-60 mg/day, titrated to maintain serum uric acid <6 mg/dl, for 24 weeks. The primary endpoint was change in the cardio-ankle vascular index (CAVI) from baseline to 24 weeks. There were no significant changes in CAVI from baseline to 24 weeks (from 9.13 to 9.16 [feboxustat] and 8.98 to 9.01 [topiroxostat]). Compared with baseline, there were significant reductions in serum uric acid (-2.9 and -2.5 mg/dl; both p < 0.001) and morning home systolic BP (-3.6 and -5.1 mm Hg; both p < 0.01) after 24 weeks' treatment with febuxostat and topiroxostat. BP decreased to the greatest extent in the subgroup of patients with uncontrolled blood pressure at baseline. Topiroxostat, but not febuxostat, significantly decreased plasma xanthine oxidoreductase activity versus baseline. The urinary albumin-creatinine ratio (UACR) decreased significantly from baseline to 24 weeks with topiroxostat (-20.8%; p = 0.021), but not febuxostat (-8.8%; p = 0.362). In conclusion, neither topiroxostat nor febuxostat had any significant effects on arterial stiffness over 24 weeks' treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.